Olaparib (AZD2281, Ku-0059436)

Catalog No.S1060

Olaparib (AZD2281, Ku-0059436) Chemical Structure

Molecular Weight(MW): 434.46

Olaparib (AZD2281, KU0059436) is a selective inhibitor of PARP1/2 with IC50 of 5 nM/1 nM in cell-free assays, 300-times less effective against tankyrase-1.

Size Price Stock Quantity  
In DMSO USD 91 In stock
USD 70 In stock
USD 150 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 92 Publications

18 Customer Reviews

  • CYREN does not regulate repair of replication-induced DSBs. Representative images of chromosomes.

    Nature, 2017, 549(7673):548-552. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    Clonogenic survival of cells expressing BARD1(WT)res or BARD1(AAE)res after treatment with olaparib or MMC. Data are means ± s.d., n = 3. EV, empty vector. P values were calculated using two-way ANOVA and multiple comparisons were corrected by the Bonferroni method. ** P < 0.01.

    Nature, 2017, 550(7676):360-365. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • a, IC50 levels of olaparib in EWS–FLI1 mutant cells (n = 17) versus breast cancers (n = 13) or pan-cancer (n = 147) dataset. b, Cell viability of IMR90 and Ewing sarcoma cells with increasing doses of olaparib. Mean ± s.d., n = 3 technical replicates, one-way ANOVA compared to IMR90 cells. c, Cell viability plot demonstrating the role of EWS–FLI1 in mediating exquisite sensitivity to olaparib in U2OS cells transfected with either the oncogene or empty vector; n = 3 transfection replicates.

    Nature, 2018, 555(7696):387-391. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    Western blot analysis showing PARylated proteins in cells subject to the indicated PARP inhibitor treatments (5 μM Olaparib and 10 μM NU1025).

    Cell, 2018, 172(3):439-453. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  •  

    SAHA and olaparib synergistically induced apoptosis and compromised DNA repair in the sensitive HCC cells. Cells were treated with 0.5 uM SAHA, 3 uM olaparib alone or in combination for 48 hours, and protein extracts were subjected to western blot analysis with the indicated antibodies.

    Hepatology 2012 55, 1840-1851. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

     

    SAHA and olaparib synergistically induced apoptosis and compromised DNA repair in the sensitive HCC cells. Cells were treated with 0.5 uM SAHA, 3 uM olaparib alone or in combination for 48 hours, and protein extracts were subjected to western blot analysis with the indicated antibodies.

    Hepatology 2012 55, 1840-1851. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  •  

    SAHA and olaparib synergistically induced apoptosis and compromised DNA repair in the sensitive HCC cells. Cells were treated with 0.5 uM SAHA, 3 uM olaparib alone or in combination for 24 (A) or 12 (B) hours, subjected to staining with propidium iodide (A) or FITC-Annexin V (B), and then analyzed by flow cytometry.

    Hepatology 2012 55, 1840-1851. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

     

    Mechanism of FK866/olaparib synergy. FK866 exacerbates levels of gH2AX caused by olaparib. CAL51 cells were exposed to FK866 and/or olaparib for 48 h and cell lysates generated and immunoblotted for total and gH2AX.

    EMBO Mol Med 2012 4, 1087-1096. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • Role of PARP and BER in the synergy between PTX and GMX in A549 cells. A) Cells were pre-treated +/- 1 uM olaparib (2h) then sequentially +/- 150nM PTX (24h) then +/- GMX 12nM (48h). Cells were harvested for (left) NAD+ quantification by LC-MS/MS (mean +/-SD of quadruplicates) or (right) viability by CellTiter-Glo (mean +/-SD of duplicates) B) PAR modification of proteins and γ-H2AX levels were measured in extracts treated as in A) by western blotting.

    Cancer Res 2014 74(21), 5948-54. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    J Exp Clin Cancer Res 2013 32(1), 95. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • (A) Representative confocal microscopy images of nuclear γ-H2AX (red) and DAPI (blue) staining in FKO1 cells 30 minutes following irradiation. Cells pre-treated for 24hr with 1μM NanoOlaparib, olaparib, or a vehicle control before irradiation.

    Mol Cancer Ther, 2017, 16(7):1279-1289. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    MSH3-deficient cells are sensitive to olaparib, a PARP inhibitor, and the combination with oxaliplatin. A, clonogenic survival of HCT11635, G5 without doxycycline (DOX), and G5 cells with doxycycline, which were treated with 2 μM of oxaliplatin, 2 μM of olaparib, and the combination of these two drugs. B, clonogenic survival of HT29 cells, which were treated with 1 μM oxaliplatin, 2 μM olaparib, and the combination of these two drugs.

     

     

    J Biol Chem 2011 286, 12157-12165. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • Logarithmic growth curves of human Burkitt lymphoma cells over 5 days with 500 nmol/l of ABT-888 and AZD-2281 in combination with 0 Gy (a), 4 Gy (b), 8 Gy (c), and 12 Gy (d) of external beam radiation. The maximal relative reduction was 65.5% of viable cells and occurred with AZD-2281 (500 nmol/l) on day 5. DMSO, dimethyl sulfoxide.

    Nucl Med Commun 2011 32, 1046-51. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    Nucl Med Commun 2011 32, 1046-51. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  •  

    Number of foci detected using laser confocal microscopy and fluorescent Fluor 647 anti-H2A.X-phosphorylated (Ser139) antibody. Double-stranded breaks (red) are clearly augmented in cells incubated with 500 nmol/l of ABT-888 and 500 nmol/l of AZD-2281 compared with PBS and 1% dimethyl sulfoxide controls. Image analysis was performed using ImageJ and the ‘analyze particle’ function.

    Nucl Med Commun 2011 32, 1046–1051 . Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    Olaparib inhibited cell proliferation, and CRC cells with high XRCC2 expression had higher olaparib sensitivity. The surviving fractions of SW480 cells treated with (A) 1 mM, (B) 10 mM, and (C) 50 mM olaparib were measured using CCK-8. (D) The relation between cell viability and olaparib concentration.

    Medicine (Baltimore) 2014 93(28), e294. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • in vivo suppression of PAR formation by the PARP inhibitor AZD2281 upon induction of DNA damage Primary human lung fibroblast cells (MRC-5) were pre-treated with the indicated concentration of the PARP inhibitor AZD2281 for two hours. Oxidative DNA damage was induced by 500 µM H2O2 for 10 min and cellular PARP activity was measured by immuno-staining of poly(ADP)-ribose (PAR) (right panels). The in vivo effect of PARP inhibition was compared to cells without DNA damage induction and inhibitor (control) and H2O2-treated cells without inhibitor. Average nuclear PAR staining intensities of more than 50 cells were statistically analysed by Kruskal-Wallis and the post-hoc Dunn’s Multiple Comparison tests (left panel). Asterisks indicate highly significant (p<1%) differences to H2O2-treated cells without PARP inhibitor. Thick horizontal bars mark medians and error bars the interquartile range.

    2010 Dr. David Schrmann from University of Base. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    Effect of AZD 2281 on the viability of endometrial cancer cell line Hec50 and Ishikawa and ovarian cancer cell line SKOV3,Caov3 and PA-1 was detected by WST-1 method after 3 days treatment.

     

     

    2010 Dr. Xiangbing Meng of University of Iowa. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

Purity & Quality Control

Choose Selective PARP Inhibitors

Biological Activity

Description Olaparib (AZD2281, KU0059436) is a selective inhibitor of PARP1/2 with IC50 of 5 nM/1 nM in cell-free assays, 300-times less effective against tankyrase-1.
Features A potent PARP inhibitor (currently in late stage clinical trials).
Targets
PARP2 [1]
(Cell-free assay)
PARP1 [1]
(Cell-free assay)
1 nM 5 nM
In vitro

Olaparib would act against BRCA1 or BRCA2 mutations. Olaparib is not sensitive to tankyrase-1 (IC50 >1 μM). Olaparib could ablate the PARP-1 activity at concentrations of 30-100 nM in SW620 cells. Olaparib is hypersensitive to BRCA1-deficient cell lines (MDA-MB-463 and HCC1937), compared with BRCA1- and BRCA2-proficient cell lines (Hs578T, MDA-MB-231, and T47D). [1] Olaparib is strongly sensitive to KB2P cells due to suppression of base excision repair by PARP inhibition, which may result in the conversion of single-strand breaks to double-strand breaks during DNA replication, thus activating BRCA2-dependent recombination pathways. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
KP3.33 NYq4NmM3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW[0JIQ> MWrJR|UxRTVwN{C1JEDPxE1i NFqzS5UyQDV3OU[xNy=>
KP6.3 Mne0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWG0JIQ> MXXJR|UxRTFyLkSyPEDPxE1i MmLlNVg2PTl4MUO=
KP7.7 NFvkZmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHT4Z5c1KGR? NI\pUohKSzVyPUW3JI5OKA>? Mk\kNVg2PTl4MUO=
KB2P3.4 M2rMT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DvV|Qh\A>? NIq0SldKSzVyPUGyOEBOKA>? M1\NTVE5PTV7NkGz
KB2P1.21 NXXWZ2x7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3tVFJQPCCm MmPNTWM2OD16OUC3JI5OKA>? M1LPXlE5PTV7NkGz
U373-MG M3nqNmN6fG:2b4jpZ{BCe3OjeR?= Mo\DNUDPxE1i M2nMSFI1KGh? M1ywbGlv[3KnYYPld{Bz[WSrYYTpc44he2Wwc3n0bZZqfHl? M4nlVlE5QTV2N{Gy
T98G NWfWWXEzS3m2b4TvfIlkKEG|c3H5 NF7rVWQyKM7:TTC= MmHNNlQhcA>? NVjnUG5jUW6lcnXhd4V{KHKjZHnheIlwdiC|ZX7zbZRqfmm2eR?= M3zHW|E5QTV2N{Gy
U87-MG NV70dFVQS3m2b4TvfIlkKEG|c3H5 MUexJO69VSB? MljDNlQhcA>? M1LFU2lv[3KnYYPld{Bz[WSrYYTpc44he2Wwc3n0bZZqfHl? M4PLeVE5QTV2N{Gy
UVW NWTN[VE4S3m2b4TvfIlkKEG|c3H5 MV[1NFAhdk1? NXryeZRuOjRiaB?= NEDoSZBKdmO{ZXHz[ZMhemGmaXH0bY9vKHOnboPpeIl3cXS7 NVXNUXM3OTh7NUS3NVI>
HeLa MoO3SpVv[3Srb36gRZN{[Xl? Mk[4OVAxKG6P NWfEPIlsPCCq NXrBeVdTS2G3c3XzJIEhdW:mZYP0JIRmdGG7IHnuJJJmcm:rbnnu[{Bw\iC{YXTpZZRqd25vaX7keYNm\CCGTlGgZpJm[Wu| NULxbm1lOTh7NUS3NVI>
HeLa M3LtZ2Z2dmO2aX;uJGF{e2G7 NYjIbFRTOSEQvF2g NW\xSpE4OjRiaB?= M4PNS2VvcGGwY3XzJJJi\GmjdHnvck1qdmS3Y3XkJHMueGijc3WgZZJz\XO2 MWOxPFk2PDdzMh?=
T98G M1;rfWZ2dmO2aX;uJGF{e2G7 NIj1d28yKM7:TTC= MlXKNlQhcA>? NUDGb402TW6qYX7j[ZMhemGmaXH0bY9vNWmwZIXj[YQhWy2yaHHz[UBienKnc4S= M2PNblE5QTV2N{Gy
L3 NU\RfG0{S3m2b4TvfIlkKEG|c3H5 MnHTOUDPxE1i NWfWbG9wQTZiaB?= Mn7jSG1UVw>? MofXV4lodmmoaXPhcpRtgSCrbnjpZol1eyClZXzsJJN2en[rdnHs MkXRNlAyOjR2NUm=
Granta-519 NGfIVHREgXSxdH;4bYMhSXO|YYm= NEL5WWk2KM7:TTC= M2[zb|k3KGh? Mmm3SG1UVw>? MXXTcIlocHSueTDpcohq[mm2czDj[YxtKHO3co\peoFt NYC5ZXloOjBzMkS0OVk>
BT M{DSc2N6fG:2b4jpZ{BCe3OjeR?= NHjR[|A2KM7:TTC= NUPNdWpKQTZiaB?= NFX0S2dFVVOR M2X4WXNtcWeqdHz5JIlvcGmkaYTzJINmdGxic4Xyeol3[Wx? MmL6NlAyOjR2NUm=
UPN2 M4HIOmN6fG:2b4jpZ{BCe3OjeR?= MnvPOUDPxE1i M3jOeVk3KGh? MknnSG1UVw>? M4\lNHNtcWeqdHz5JIlvcGmkaYTzJINmdGxic4Xyeol3[Wx? NFvTboszODF{NES1PS=>
HBL-2 NEHuNoREgXSxdH;4bYMhSXO|YYm= Mk\uOUDPxE1i MoL4PVYhcA>? M{\P[GROW09? MknzV4xq\2i2bImgbY5pcWKrdIOgZ4VtdCC|dYL2bZZidA>? M4D5UlIxOTJ2NEW5
JVM-2 NWPJNYdES3m2b4TvfIlkKEG|c3H5 Ml\1OUDPxE1i MX65OkBp M4TnRWROW09? M2nH[3NtcWeqdHz5JIlvcGmkaYTzJINmdGxic4Xyeol3[Wx? M1jLT|IxOTJ2NEW5
Z138 MWPDfZRwfG:6aXOgRZN{[Xl? MVe1JO69VSB? M3:zcFk3KGh? Mn;zSG1UVw>? NVzjfo1HW2yrZ3j0cJkhcW6qaXLpeJMh[2WubDDzeZJ3cX[jbB?= Ml;NNlAyOjR2NUm=
RWPE NWK3Z|M2UW64YYPpeoUhSXO|YYm= NYS4PIdoOjVizszN MmDIOFghcA>? Mm\sSG1UVw>? Ml;ZV4lodmmoaXPhcpRtgSC{ZXT1Z4V{KEWURz3kdol3\W5iY3XscEBqdn[jc3nvci=> MlTwNlE2PzV6NkW=
VCaP MmDLTY53[XOrdnWgRZN{[Xl? NULOcnVGOjVizszN NVHFfpFTPDhiaB?= MUjEUXNQ MoOyV4lodmmoaXPhcpRtgSC{ZXT1Z4V{KEWURz3kdol3\W5iY3XscEBqdn[jc3nvci=> NY[3U|dJOjF3N{W4OlU>
Mouse H2AX−/− ES Cells MoHpR5l1d3SxeHnjJGF{e2G7 M{fMcVIvPSEQvF2= NEf5UnQzOCCq M3v0fXNq\26rZnnjZY51dHliaX7obYJqfHNiY3XscEB{fXK4aY\hcC=> M{XhflI{OzV3NEi5
Mouse ATM−/− ES Cells NIjmXnZEgXSxdH;4bYMhSXO|YYm= NHTTd20zNjVizszN M{jzWlIxKGh? MljLV4lodmmoaXPhcpRtgSCrbnjpZol1eyClZXzsJJN2en[rdnHs M{jJTVI{OzV3NEi5
H1650 NHSwfpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTncm0zOCEQvF2= MWqxOFQhcA>? M3nHSGlEPTB;MUWuOFch|ryP NYXS[2U3OjN{M{m4NFk>
H1650PTEN+ MmXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XVVVIxKM7:TR?= MYCxOFQhcA>? Mn73TWM2OD13MD64N{DPxE1? M2HEPFI{OjN7OEC5
PC-9 Mkn4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDDeXFTOjBizszN NVTLXHJ2OTR2IHi= MoDDTWM2OD13Lki4JO69VQ>? NUXoOXhzOjN{M{m4NFk>
PC-9PTEN− MmLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3xNlAh|ryP MVexOFQhcA>? MW\JR|UxRTZwNUKg{txO NF7RXWYzOzJ|OUiwPS=>
MDA-MB-231 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1T3b|Uh\GG7 MXzJR|UxRTZwOTFOwG0> MlO1NlM4PjB2OU[=
MDA-MB-468 NEnZTYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLGOUBl[Xl? MkXkTWM2OD13LkCg{txO MYqyN|c3ODR7Nh?=
BT20 MmXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3f6cFUh\GG7 NW\PbI1jUUN3ME23Mlch|ryP NX\iN|VtOjN5NkC0PVY>
HCC1143 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XCdlUh\GG7 NV;IN|NqUUN3ME2xNU4yKM7:TR?= MUSyN|c3ODR7Nh?=
HCC1937 NYTJc41LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnNV4Y3PSCmYYm= NXf2NXMxUUN3ME2xNk43KM7:TR?= M{\5UVI{PzZyNEm2
Hs578t NFrlVFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVu1JIRigQ>? MXrJR|UxRTVwNjFOwG0> M2DlUVI{PzZyNEm2
Hs578t(si) MnLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfCOUBl[Xl? MX;JR|UxRTdwNTFOwG0> NGC1XYYzOzd4MES5Oi=>
BT474 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXRfGlyPSCmYYm= MXrJR|UxRTF7Lkig{txO M2\0cFI{PzZyNEm2
JIMT1 NGX4coRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjSWWQ2KGSjeR?= NFnGV5VKSzVyPUeuO{DPxE1? MXmyN|c3ODR7Nh?=
SKBR3 NVfNXFFzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYD1RohqPSCmYYm= MVnJR|UxRTFzLkGg{txO MYCyN|c3ODR7Nh?=
SUM159 NXHzSXhYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzDR3M2KGSjeR?= MVvJR|UxRTRwMjFOwG0> MXiyN|c3ODR7Nh?=
CAMA1 NGTHTWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVe1S4VxPSCmYYm= MlPyTWM2OD1zNT64JO69VQ>? NYPjSoNHOjN5NkC0PVY>
MCF7 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoWwOUBl[Xl? M3HEdWlEPTB;NT64JO69VQ>? NXzpTI84OjN5NkC0PVY>
T47D M3TqOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDkdFdoPSCmYYm= NVLu[FJmUUN3ME25MlYh|ryP MWWyN|c3ODR7Nh?=
HCT116 NUfaOXNuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmW4NVAxKM7:TR?= Mnq5OFghcA>? MWPEUXNQ M1v5fmlEPTB;Mj61JO69VSB? M2rzO|I1PTd5OUSx
SW1116 NXmwTFF6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13ZdlExOCEQvF2= NX;WcHpsPDhiaB?= NVm5fog3TE2VTx?= NUDkZ21zUUN3ME2xNFAh|ryP NXXzOnQ5OjR3N{e5OFE>
HT29 MmjjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLhOY1zOTByIN88US=> NFPtWJU1QCCq MWPEUXNQ NUfUcVg4UUN3ME2xOE44KM7:TR?= M{XaNFI1PTd5OUSx
LoVo Mm\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnG1NVAxKM7:TR?= MVq0PEBp M1S3SGROW09? MlfYTWM2OD1zMz60JO69VQ>? MofYNlQ2Pzd7NEG=
HCT-15 NXHafFFUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfNXJMyOTByIN88US=> NHvvboE1QCCq MVPEUXNQ M4PTe2lEPTB;MUCg{txO NIXrbXAzPDV5N{m0NS=>
SW48 M2nHN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjkW|FsOTByIN88US=> NXHwfo5yPDhiaB?= MljySG1UVw>? NH61UpVKSzVyPUmuOUDPxE1? NEezfZkzPDV5N{m0NS=>
C-1 M3WyO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHJR4hMOTByIN88US=> MVG0PEBp MoD4SG1UVw>? M{LLZ2lEPTB;Nz62JO69VQ>? Mn7FNlQ2Pzd7NEG=
RKO MnW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXuxNFAh|ryP MYm0PEBp NEXKd4pFVVOR NGrwbplKSzVyPUWuPUDPxE1? MXWyOFU4Pzl2MR?=
HCT116 M3nKdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLQNVAxKM7:TR?= NWnObnpsPDhiaB?= MWLEUXNQ MXzQc5RmdnSrYYTld{BUVi1|ODDjfZRwfG:6aXPpeJkh M3LOV|I1PTd5OUSx
SW1116 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYmxNFAh|ryP M3jLSFQ5KGh? Mn3OSG1UVw>? NWrLZmt1WG:2ZX70bYF1\XNiU16tN|gh[3m2b4TvfIlkcXS7IB?= NVK0UmZZOjR3N{e5OFE>
HT29 MlPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPRNVAxKM7:TR?= NFrLcXY1QCCq MXHEUXNQ MX;Qc5RmdnSrYYTld{BUVi1|ODDjfZRwfG:6aXPpeJkh MXuyOFU4Pzl2MR?=
LoVo NUnQTYJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXz1WnRKOTByIN88US=> NWfpWVJLPDhiaB?= NXjkboVYTE2VTx?= NXGyTVhOWG:2ZX70bYF1\XNiU16tN|gh[3m2b4TvfIlkcXS7IB?= MoTvNlQ2Pzd7NEG=
SW48 NEHWc|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjnbGN7OTByIN88US=> NYPReJZuPDhiaB?= MoTqSG1UVw>? NIG2RnZRd3SnboTpZZRmeyCVTj2zPEBkgXSxdH;4bYNqfHli MVSyOFU4Pzl2MR?=
C-1 NEfqd2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFO5elgyODBizszN MUe0PEBp MoDjSG1UVw>? MlyxVI91\W62aXH0[ZMhW05vM{igZ5l1d3SxeHnjbZR6KA>? MV:yOFU4Pzl2MR?=
RKO NWLOT4kzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnhNVAxKM7:TR?= NEjlUnY1QCCq MXrEUXNQ MmXCVI91\W62aXH0[ZMhW05vM{igZ5l1d3SxeHnjbZR6KA>? Mo[zNlQ2Pzd7NEG=
HCT116 MnHSSpVv[3Srb36gRZN{[Xl? NUHwcVZCOTBibl2= M3;ZVFEzKGh? NWTSeII2TE2VTx?= MVPJcoNz\WG|ZYOgSG5CKGSxdXLs[U1{fHKjbnSgZpJm[Wu|IHnu[JVk\WRiYomgV24uOzh? M4PHUFI1PTd5OUSx
HT29 NVfENI9xTnWwY4Tpc44hSXO|YYm= MlH3NVAhdk1? M1zifVEzKGh? M2W3R2ROW09? M2\sNGlv[3KnYYPld{BFVkFiZH;1ZoxmNXO2cnHu[EBjemWja4OgbY5lfWOnZDDifUBUVi1|OB?= NVuzcWtTOjR3N{e5OFE>
TE-6 M2TITGZ2dmO2aX;uJGF{e2G7 NFnuTmQ2KM7:TTC= MYSxNkBp NID0cVVFVVOR MWfJcoR2[2W|IFeyM20h[XK{ZYP0 MnniNlQzOTlzNkS=
TE-6 M2PUe2Z2dmO2aX;uJGF{e2G7 NHzSVZM2KM7:TTC= NGr2W|kzPCCq M1\rfGROW09? NVfodVdMUW6lcnXhd4V{KGmwIHTveYJt\SC|dILhcoQh[nKnYXvzJEhFW0K|KR?= NXvGOllwOjR{MUmxOlQ>
Hep3B NHTvTHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjhPZg1OCEQvF2g Mlr1O|IhcA>? M1vKSWROW09? NIXpelRUgW6ncnfpd5Rq[2GubImgbY5pcWKrdIOgZ4VtdCCpcn;3eIghf2m2aDDETG1GWQ>? NGm0fpUzPTB5Mke1Ni=>
Huh7 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPYPIE1OCEQvF2g MV[3NkBp MYrEUXNQ NFXQbpFUgW6ncnfpd5Rq[2GubImgbY5pcWKrdIOgZ4VtdCCpcn;3eIghf2m2aDDETG1GWQ>? MlHWNlUxPzJ5NUK=
Hep3B NWm1PGR1TnWwY4Tpc44hSXO|YYm= NF\3Z4w1OCEQvF2g NVPZS3pOOjRiaB?= M4DWeGROW09? M{HN[mlv\HWlZYOgVm9UKHC{b3T1Z5Rqd25id3n0bEBFUE2HUR?= NVzmOmdOOjVyN{K3OVI>
Huh7 MVnGeY5kfGmxbjDBd5NigQ>? MlvIOFAh|ryPIB?= MmPNNlQhcA>? MUXEUXNQ MVvJcoR2[2W|IGLPV{Bxem:mdXP0bY9vKHerdHigSGhOTVF? NETwe3AzPTB5Mke1Ni=>
Hep3B NWn6eotSTnWwY4Tpc44hSXO|YYm= M1q0WVQxKM7:TTC= NWjRSXFwOjRiaB?= Ml7DSG1UVw>? MnWwTY5lfWOnczDj[YxtKGG3dH;wbIFogSC5aYToJGRJVUWT NVP3THhLOjVyN{K3OVI>
Huh7 M4rHeWZ2dmO2aX;uJGF{e2G7 MnzZOFAh|ryPIB?= MWSyOEBp MmTSSG1UVw>? NH3te3RKdmS3Y3XzJINmdGxiYYX0c5Bp[We7IIfpeIghTEiPRWG= MUSyOVA4Ojd3Mh?=
SGC-7901 M4K5Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVWzNOKh|ryP M4LBelQ5KGh? NX\1[oh[TE2VTx?= NX7HUm46SmyxY3ugc5hidGmybHH0bY4ucW6mdXPl[EBk\WyuIHTlZZRp NWK2ZWdlOjV5NkewO|Y>
COLO-800 Mle2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHj3R3pKSzVyPUCuOFQyPjRizszN MmnoV2FPT0WU
EoL-1- M3njemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTBwNU[0OFYh|ryP NGC1Wm9USU6JRWK=
NCI-H209 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTBwOUG1OVYh|ryP M3i5eXNCVkeHUh?=
ES1 NVnjSms{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrpWol5UUN3ME2xMlEyPDB6IN88US=> NFjPc4VUSU6JRWK=
NKM-1 NXTaRnlnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;uTWM2OD1zLkK1N|Q4KM7:TR?= MlixV2FPT0WU
NTERA-S-cl-D1 M4LZXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmCyTWM2OD1zLkOzN|QyKM7:TR?= MoXhV2FPT0WU
MHH-ES-1 M2HQ[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nmPWlEPTB;MT62NlA3PyEQvF2= M1n0U3NCVkeHUh?=
ES8 NX\YVlh6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmiyTWM2OD1zLkeyOFE1KM7:TR?= MWPTRW5ITVJ?
NCI-H720 M33VT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTJwMkC2PVkh|ryP NHjsU2ZUSU6JRWK=
EW-3 NFXETG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXkTGRKSzVyPUKuNlc2OzRizszN NX;xNZBWW0GQR1XS
D-566MG MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTJwNES1Olgh|ryP MUHTRW5ITVJ?
697 NIfVeFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXKXIdxUUN3ME2yMlg1OTd|IN88US=> MX;TRW5ITVJ?
ES5 M{KzOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTJwOEixPFkh|ryP Ml3wV2FPT0WU
COLO-684 MoHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37IeGlEPTB;Mz61NVY6PiEQvF2= NGS0Z4pUSU6JRWK=
ML-2 NWLzXIlxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTNwNkCwOVgh|ryP NG[1dWxUSU6JRWK=
MC-IXC MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;TOGpKSzVyPUOuOlM{QTNizszN MVXTRW5ITVJ?
DB MlzMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LkSWlEPTB;Mz62OVQ1QCEQvF2= NEjlTYRUSU6JRWK=
HCC2218 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{C1OmlEPTB;Mz63N|ExOyEQvF2= MYTTRW5ITVJ?
NCI-H510A M2H4[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmX0TWM2OD1|LkiyO|I1KM7:TR?= M3iwOXNCVkeHUh?=
NCI-H526 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TES2lEPTB;Mz64Olk2QCEQvF2= M{[3dHNCVkeHUh?=
MV-4-11 NVzhXYZkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzPZY1KSzVyPUSuNVM{OzRizszN M3LEcXNCVkeHUh?=
PA-1 NFLrNY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{iz[GlEPTB;ND6yOVI6KM7:TR?= M2q1[nNCVkeHUh?=
EW-22 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlGwTWM2OD12LkO1PFYh|ryP Mn3HV2FPT0WU
KASUMI-1 MoXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTQR2FQUUN3ME20MlQxOTB7IN88US=> Mn\VV2FPT0WU
LU-139 M1n4XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTRwN{W4Nlkh|ryP NYnrbWZTW0GQR1XS
SBC-1 M3PVZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rzSGlEPTB;ND64NFkxQCEQvF2= NYTLXmFvW0GQR1XS
H4 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTRwOEm0OFMh|ryP M3XKWXNCVkeHUh?=
EW-11 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjJc5dKSzVyPUWuNFgxPzJizszN NWW4XYk4W0GQR1XS
NBsusSR M3fwZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF[2NnFKSzVyPUWuNVIxPTVizszN M1rH[HNCVkeHUh?=
RPMI-8226 M4jlXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTVwMUWyOFQh|ryP Mk\6V2FPT0WU
DEL M{S2dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTVwMkCwNFYh|ryP NUHpR5J{W0GQR1XS
ES4 NHvTVVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1SxOWlEPTB;NT61NVM5QSEQvF2= Ml7tV2FPT0WU
GCT NGS1e4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY[zVoRKUUN3ME21MlU3QDV4IN88US=> MVXTRW5ITVJ?
NCI-H1048 NUPmWlFDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTXO3BKSzVyPUWuPVczPzNizszN NHHlZ5BUSU6JRWK=
NCI-SNU-1 MmP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTZwMEKyJO69VQ>? NETZephUSU6JRWK=
ES7 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFy5cYJKSzVyPU[uNFM2PzdizszN NFvRRo5USU6JRWK=
SW982 MkWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTZwMEmxN|ch|ryP M{nNXHNCVkeHUh?=
L-363 Mn7iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHNTWM2OD14LkOzPVc1KM7:TR?= M1;rXHNCVkeHUh?=
HT-1080 NWThbYZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkflTWM2OD14LkS5Olg{KM7:TR?= M2DPOXNCVkeHUh?=
HAL-01 Mn;DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojZTWM2OD14LkWxNFkh|ryP MYLTRW5ITVJ?
NB14 NVXmSGluT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;FUGlEPTB;Nj62OFA{QSEQvF2= M1vy[HNCVkeHUh?=
EW-13 M2Txe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnJTWM2OD14Lke3OFI1KM7:TR?= MoPPV2FPT0WU
NY MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDl[ndNUUN3ME22Mlk1PjB3IN88US=> NWLCR4xqW0GQR1XS
NCI-SNU-5 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fkT2lEPTB;Nz6xNFQ{OyEQvF2= NEL5cXZUSU6JRWK=
MS-1 NXnVWWlpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\zUYFKSzVyPUeuNVc1QTRizszN MnzBV2FPT0WU
EW-16 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoqyTWM2OD15LkOxPFYyKM7:TR?= M2HleHNCVkeHUh?=
LU-65 M2nzcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTxdlVKSzVyPUeuOFg1OTdizszN M37HXHNCVkeHUh?=
HGC-27 NWKxfWFZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnWTWM2OD15LkeyNVc{KM7:TR?= MXPTRW5ITVJ?
CTB-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\6eGlEPTB;Nz63OlE4PSEQvF2= NX35XpVKW0GQR1XS
5637 MkDKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTdwOUK4OkDPxE1? NXWwUIVXW0GQR1XS
U251 M3yyUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PsVWlEPTB;Nz65OFAyPiEQvF2= M4DvRnNCVkeHUh?=
HOS NIDyfIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTWbYNxUUN3ME24MlI{ODB5IN88US=> M2rRSXNCVkeHUh?=
DOHH-2 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfoeIFiUUN3ME24MlI{PThizszN Mmj0V2FPT0WU
EW-1 NFPyT|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrkTWM2OD16LkOwNFg5KM7:TR?= MlzpV2FPT0WU
BV-173 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnyTWM2OD16LkW1OVQh|ryP NV3QRppIW0GQR1XS
8-MG-BA MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnOcJpvUUN3ME24MlY5QTh6IN88US=> MXvTRW5ITVJ?
NB69 NH:5T2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRThwN{C5NlEh|ryP NVPPNm9yW0GQR1XS
NCI-H69 M3TRcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorjTWM2OD17LkmwPVYyKM7:TR?= M2nUV3NCVkeHUh?=
RS4-11 NIPJ[GtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHz4N5FKSzVyPUGxMlIzODhizszN NH;lNlZUSU6JRWK=
ONS-76 MkjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LWXWlEPTB;MUGuNlk1PyEQvF2= MWPTRW5ITVJ?
SF539 MlXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnvTWJKSzVyPUGxMlQ5QDlizszN NUjLR|JsW0GQR1XS
HuO-3N1 M{DDW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnHSllKSzVyPUGxMlU4QTZizszN NH\tN5NUSU6JRWK=
NCI-H1651 M1:2Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUW0SIM2UUN3ME2xNk4{OTF3IN88US=> MoHGV2FPT0WU
KARPAS-45 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLWTWM2OD1zMj6zO|Yh|ryP MWjTRW5ITVJ?
SK-NEP-1 NIX6XpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPV[4xKSzVyPUGyMlQ3ODlizszN NVjYfY45W0GQR1XS
LAMA-84 M3XIT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2[xXWlEPTB;MUOuNVA6PSEQvF2= NFXGZY5USU6JRWK=
NCI-H1155 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTF|LkK4OVYh|ryP M{\oZ3NCVkeHUh?=
CTV-1 M{HIcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHz6UGFKSzVyPUGzMlQ1PSEQvF2= MWPTRW5ITVJ?
QIMR-WIL NFPOXYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HrV2lEPTB;MUOuO|gyPCEQvF2= NHjZb2NUSU6JRWK=
H9 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MluyTWM2OD1zMz64OFc2KM7:TR?= MWTTRW5ITVJ?
SK-MEL-1 NFW4[3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYWyW|V5UUN3ME2xN{46OzR5IN88US=> MnzOV2FPT0WU
HD-MY-Z M2juO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDTWHhXUUN3ME2xOE4xPjN5IN88US=> NUPzeVkyW0GQR1XS
TI-73 NXS2[3g3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PudmlEPTB;MUSuNlM2PiEQvF2= M3;CfHNCVkeHUh?=
JVM-3 NHvPXI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvMfJpKSzVyPUG1MlU4OTZizszN M3\p[HNCVkeHUh?=
D-247MG MkXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHxTWM2OD1zNT61PVMh|ryP M4\k[HNCVkeHUh?=
VA-ES-BJ M2Lucmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHrfZQ3UUN3ME2xOU43ODl5IN88US=> NIG2cG9USU6JRWK=
NOS-1 MmrhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4j1TmlEPTB;MUWuOlUzOiEQvF2= MY\TRW5ITVJ?
MOLT-4 M3nRb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7rdZJtUUN3ME2xOk44PTJizszN NWDEfmt2W0GQR1XS
Mo-T NYrrSIdKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTF5LkC4OFkh|ryP NFXJN5RUSU6JRWK=
NCI-H1770 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojVTWM2OD1zNz6xOVQ{KM7:TR?= NILoXoNUSU6JRWK=
COLO-320-HSR MmrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XtUmlEPTB;MUeuNVgzPyEQvF2= MUPTRW5ITVJ?
TE-12 Mm\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3ZN3h3UUN3ME2xO{44ODV2IN88US=> M3PnTXNCVkeHUh?=
NCI-H82 NE\FUGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnYTWM2OD1zNz64O|I5KM7:TR?= MVvTRW5ITVJ?
NEC8 M2rUU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYf0b|hGUUN3ME2xPE4yOzF4IN88US=> M4LnNXNCVkeHUh?=
HSC-3 NWnYNY5GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrVTWM2OD1zOD63OFE1KM7:TR?= M1q4O3NCVkeHUh?=
NCI-H1092 MnfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjHR4NKSzVyPUG4Mlc2QTVizszN NFe0XW9USU6JRWK=
NCI-H292 M1znXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTF7LkC0PFkh|ryP NHLmdG9USU6JRWK=
L-428 NYX0W2RVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTF7LkW1PUDPxE1? Mn\oV2FPT0WU
LU-134-A MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHQTWM2OD1zOT61O|Ih|ryP NFTVWFZUSU6JRWK=
GI-ME-N NWS1eVhwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVy4dlBIUUN3ME2xPU42PzR5IN88US=> NW\PTHh1W0GQR1XS
ALL-PO MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTF7LkW5O|Ih|ryP MWLTRW5ITVJ?
D-283MED NF7WTpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TMRmlEPTB;MUmuPVE2KM7:TR?= NULNS2R7W0GQR1XS
D-423MG MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HVO2lEPTB;MUmuPVk3PyEQvF2= NH3zV3hUSU6JRWK=
CAKI-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\oVXZJUUN3ME2yNE4zOjF7IN88US=> NVLhdVdZW0GQR1XS
ETK-1 NGGyPZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M320dGlEPTB;MkCuNlYyPSEQvF2= MnXEV2FPT0WU
G-402 NFjtdotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;M[oV3UUN3ME2yNE42OzN2IN88US=> M2rrO3NCVkeHUh?=
HL-60 MkXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmmwTWM2OD1{MT6xOlE{KM7:TR?= M2fx[HNCVkeHUh?=
A2058 NXzWVnV5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjjUmtPUUN3ME2yNU41PDd5IN88US=> NVftXpkxW0GQR1XS
CHP-212 NEjGR4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLNWVdVUUN3ME2yNU46ODVzIN88US=> M1POOHNCVkeHUh?=
KY821 NWnQbXRsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTJzLkm3OUDPxE1? MorPV2FPT0WU
TYK-nu MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HmOWlEPTB;MkKuNFY2OSEQvF2= Mni2V2FPT0WU
JVM-2 NWjseVU1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfiT3dKSzVyPUKyMlI6QDNizszN NUfNbmRNW0GQR1XS
KU812 NH7UTZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4H4NmlEPTB;MkKuO|MyOiEQvF2= M33yenNCVkeHUh?=
MKN28 M1jMZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfSd25KSzVyPUKyMlkxOTVizszN NVOzWYVSW0GQR1XS
ECC10 M3iwb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTJ|Lke0NUDPxE1? NVXCbVhuW0GQR1XS
BHT-101 NFXlV3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTJ2LkCwNFgh|ryP MXPTRW5ITVJ?
DU-4475 NX;he2hTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rWUGlEPTB;MkSuN|M{PyEQvF2= MoXjV2FPT0WU
769-P NUTvR4UyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfHTWM2OD1{ND64OFY3KM7:TR?= M{\2TXNCVkeHUh?=
HEC-1 NFe2c3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XYUmlEPTB;MkWuOFQ2KM7:TR?= NVzF[WhmW0GQR1XS
MOLT-13 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTJ3LkWzN|Eh|ryP NWD4OYx3W0GQR1XS
8505C NFSxWFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPoNGp1UUN3ME2yOk41QTd5IN88US=> M336e3NCVkeHUh?=
GB-1 NE\0Z2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrMbndIUUN3ME2yOk44OTd4IN88US=> NFPRVYVUSU6JRWK=
SF126 M1\hW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7oNXZKSzVyPUK2Mlc3PDhizszN MX\TRW5ITVJ?
A4-Fuk NWjyNoJOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXDTWM2OD1{Nz6xNlcyKM7:TR?= NI\RWWZUSU6JRWK=
OVCAR-8 NFXKUZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPzTWM2OD1{Nz6xOVM6KM7:TR?= MVPTRW5ITVJ?
NCI-H1304 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGG0eZhKSzVyPUK3MlU1KM7:TR?= MorHV2FPT0WU
GR-ST NW\afIpTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3PTItKSzVyPUK4MlA1PyEQvF2= NIW0NYFUSU6JRWK=
G-401 MoS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTJ6LkWwPVYh|ryP M4DLTHNCVkeHUh?=
LXF-289 MnvWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTJ6LkW2OVEh|ryP NUDIXW9[W0GQR1XS
DBTRG-05MG NYm1T4RFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;ib29KSzVyPUK4MlkzODRizszN NF3JbGNUSU6JRWK=
YKG-1 M4LHNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4f6UGlEPTB;MkmuPFY5KM7:TR?= NFLMXJNUSU6JRWK=
GAMG M1vqZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\rc|RKSzVyPUK5Mlk6OyEQvF2= MX;TRW5ITVJ?
HCT-116 Ml7QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnNbIFKSzVyPUOwMlA2PDhizszN MnHiV2FPT0WU
S-117 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zIb2lEPTB;M{GuNlI2PyEQvF2= M2The3NCVkeHUh?=
NCI-H1693 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHHTWM2OD1|Mz62OVQzKM7:TR?= MoLZV2FPT0WU
A427 MnTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFS0N25KSzVyPUOzMlk6PzZizszN Mo\kV2FPT0WU
HT-29 M4q1[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjafoJJUUN3ME2zOE43ODN{IN88US=> NHTnOYVUSU6JRWK=
P12-ICHIKAWA NUTBc4VTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvyTWM2OD1|ND63OFkyKM7:TR?= MV7TRW5ITVJ?
CAL-51 MmfDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTN3LkC3NFkh|ryP M1npZnNCVkeHUh?=
Ramos-2G6-4C10 M3zsbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zZT2lEPTB;M{WuNlQzPSEQvF2= NEDmOZRUSU6JRWK=
SCH M1WwVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnJV3FKSzVyPUO2MlQyPzRizszN NYT0Zo56W0GQR1XS
SK-MEL-24 NULs[VM3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXS5eZA{UUN3ME2zOk46ODR2IN88US=> MoTaV2FPT0WU
SW1573 NHTHVllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPFdG5KSzVyPUO4MlczOTZizszN M3PjTXNCVkeHUh?=
BALL-1 NEHzW|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTN7LkKxNlkh|ryP NI\yeHlUSU6JRWK=
BE-13 NHHsN4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTN7LkOyPUDPxE1? NY\oOow6W0GQR1XS
GI-1 M1LKdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLkTWM2OD1|OT64OlQ4KM7:TR?= MXHTRW5ITVJ?
GOTO M4PkRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV2yOW9VUUN3ME2zPU46OTN7IN88US=> MUXTRW5ITVJ?
A673 M2n3R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrmTWM2OD12MT6wN|Q{KM7:TR?= MU\TRW5ITVJ?
KG-1 NGjz[4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTR|LkO5OEDPxE1? NUHxeppbW0GQR1XS
GP5d M4r6R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDFTWM2OD12ND6wOlY3KM7:TR?= NH7BRYRUSU6JRWK=
MFM-223 M3jT[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\oOmlEPTB;NESuNVIzQCEQvF2= MojIV2FPT0WU
OAW-42 NYe5dop2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHvTWM2OD12ND6yOlQ{KM7:TR?= NV3TSYZYW0GQR1XS
C8166 MnriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TjU2lEPTB;NEWuNFgzOiEQvF2= M{PsVnNCVkeHUh?=
LU-99A NVu4eZh3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfQTWM2OD12Nj6xN|IzKM7:TR?= M1fBPXNCVkeHUh?=
NCI-H23 MlHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHHTWM2OD12Nj6xO|g2KM7:TR?= MlrkV2FPT0WU
HO-1-N-1 NHXDdJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIr0V3dKSzVyPUS3MlA6QThizszN NU\TOolEW0GQR1XS
A3-KAW M{HreWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;DTWM2OD12Nz6xNFA4KM7:TR?= Mlv5V2FPT0WU
CGTH-W-1 MkPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13CdWlEPTB;NEeuOVA3QSEQvF2= M2D3R3NCVkeHUh?=
DJM-1 M{PjfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vS[GlEPTB;NEeuOVQyOyEQvF2= NVfFSItpW0GQR1XS
A101D M3zCfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEi0d3JKSzVyPUS3MlY{PTdizszN Mmi0V2FPT0WU
BB30-HNC MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTR6LkOwO|Ih|ryP M1\ObHNCVkeHUh?=
T98G Mn7tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PVUmlEPTB;NEiuOFY{OyEQvF2= NHXCR3ZUSU6JRWK=
NCI-H1573 Mn;nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LUV2lEPTB;NEmuOFQ3OiEQvF2= NYe1VXZnW0GQR1XS
MEG-01 NW[xXJh7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTR7Lke0NVEh|ryP NHHUeo1USU6JRWK=
WM-115 MlzaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfGboZKSzVyPUS5MlkzOjJizszN NEHFdGNUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo Combining with temozolomide, Olaparib (10 mg/kg, p.o.) significantly suppresses tumor growth in SW620 xenografts. [1] Olaparib shows great response to Brca1-/-;p53-/- mammary tumors (50 mg/kg i.p. per day), while no responses to HR-deficient Ecad-/-;p53-/- mammary tumors. Olaparib even does not show dose-limiting toxicity in tumor-bearing mice. [3] Olaparib has been used to treat with BRCA mutated tumors, such as ovarian, breast and prostate cancers. Moreover, Olaparib shows selectively inhibition to ATM (Ataxia Telangiectasia Mutated)-deficient tumor cells, which indicates to be a potential agent for treating ATM mutant lymphoid tumors. [4]

Protocol

Kinase Assay:

[1]

+ Expand

FlashPlate assay (96-well screening assay):

To columns 1 through 10, 1 μL of Olaparib (in DMSO) is added, and 1 μL DMSO only is added to the positive (POS) and negative (NEG) control wells (columns 11 and 12, respectively) of a pretreated FlashPlate. PARP-1 is diluted 1:40 in buffer (buffer B: 10% glycerol (v/v), 25 mM HEPES, 12.5 mM MgCl2,50 mM KCl, 1 mM DTT, 0.01% NP-40 (v/v), pH 7.6) and 40 μL added to all 96 wells (final PARP-1 concentration in the assay is ~1 ng/μL). The plate is sealed and shaken at RT for 15 min. Following this, 10 μL of positive reaction mix (0.2 ng/μL of double-stranded oligonucleotide [M3/M4] DNA per well, 5 μM of NAD+ final assay concentration, and 0.075 μCi 3H-NAD+ per well) is added to the appropriate wells (columns 1-11). The negative reaction mix, lacking the DNA oligonucleotide, is added to column 12 (with the mean negative control value used as the background). The plate is resealed and shaken for a further 60 min at RT to allow the reaction to continue. Then, 50 μL of ice-cold acetic acid (30%) is added to each well to stop the reaction, and the plate is sealed and shaken for a further 60 min at RT. Tritiated signal bound to the FlashPlate is then determined in counts per minute (CPM) using the TopCount plate reader.
Cell Research:

[1]

+ Expand
  • Cell lines: Breast cancer cell lines including SW620 colon, A2780 ovarian, HCC1937, Hs578T, MDA-MB-231, MDA-MB-436, and T47D
  • Concentrations: 1-300 nM
  • Incubation Time: 7-14 days
  • Method:

    The cytotoxicity of Olaparib is measured by clonogenic assay. Olaparib is dissolved in DMSO and diluted by culture media before use. The cells are seeded in six well plates and left to attach overnight. Then Olaparib is added at various concentrations and the cells are incubated for 7-14 days. After that the surviving colonies are counted for calculating the IC50.


    (Only for Reference)
Animal Research:

[3]

+ Expand
  • Animal Models: Brca1-/-;p53-/- mammary tumors are generated in K14cre;Brca1F/F;p53F/F mice.
  • Formulation: 50 mg/mL stocks in DMSO with 10% 2-hydroxyl-propyl-β-cyclodextrine/PBS
  • Dosages: 50 mg/kg
  • Administration: Administered via i.p. injection at 10 μL/g of body weight
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 86 mg/mL warmed (197.94 mM)
Water 0.002 mg/mL (0.0 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
4% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 434.46
Formula

C24H23FN4O3

CAS No. 763113-22-0
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03561870 Not yet recruiting Recurrent IDH|Mutant High Grade Glioma Hospices Civils de Lyon December 1 2019 Phase 2
NCT03561870 Not yet recruiting Recurrent IDH|Mutant High Grade Glioma Hospices Civils de Lyon December 1 2019 Phase 2
NCT03741426 Not yet recruiting Renal Cell Cancer CCTU- Cancer Theme|University of Cambridge|AstraZeneca|Cancer Research UK|Cambridge University Hospitals NHS Foundation Trust July 25 2019 Phase 2
NCT03741426 Not yet recruiting Renal Cell Cancer CCTU- Cancer Theme|University of Cambridge|AstraZeneca|Cancer Research UK|Cambridge University Hospitals NHS Foundation Trust July 25 2019 Phase 2
NCT03880019 Not yet recruiting Stage III Uterine Corpus Leiomyosarcoma AJCC v8|Stage IIIA Uterine Corpus Leiomyosarcoma AJCC v8|Stage IIIB Uterine Corpus Leiomyosarcoma AJCC v8|Stage IIIC Uterine Corpus Leiomyosarcoma AJCC v8|Stage IV Uterine Corpus Leiomyosarcoma AJCC v8|Stage IVA Uterine Corpus Leiomyosarcoma AJCC v8|Stage IVB Uterine Corpus Leiomyosarcoma AJCC v8 National Cancer Institute (NCI) June 7 2019 Phase 2
NCT03842228 Not yet recruiting Advanced Malignant Solid Neoplasm|ARID1A Gene Mutation|ATM Gene Mutation|ATRX Gene Mutation|BARD1 Gene Mutation|BRCA1 Gene Mutation|BRCA2 Gene Mutation|BRIP1 Gene Mutation|CDK12 Gene Mutation|CHEK1 Gene Mutation|CHEK2 Gene Mutation|FANCA Gene Mutation|FANCL Gene Mutation|Metastatic Malignant Solid Neoplasm|MRE11 Gene Mutation|MSH2 Gene Mutation|PALB2 Gene Mutation|PARP1 Gene Mutation|PIK3CA Gene Mutation|POLD1 Gene Mutation|PPP2R2A Gene Mutation|PTEN Gene Mutation|RAD51B Gene Mutation|RAD51C Gene Mutation|RAD51D Gene Mutation|RAD54L Gene Mutation|Unresectable Malignant Solid Neoplasm|XRCC2 Gene Mutation National Cancer Institute (NCI) June 10 2019 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How to prepare the solution of the compound (S1060) for in vivo study?

  • Answer:

    We recommend the following formulation: 4% DMSO+30% PEG300+ 66%H2O. It is a clear solution and can be used for IP injection.

  • Question 2:

    I saw that the solubility of the compound for in vivo on the website had been changed, why the change has been made?

  • Answer:

    For the formulation for in vivo, the compound dissolving in 15% Captisol (former solubility) is a suspension, and it is fine for oral gavage. And now, dissolving in 4% DMSO+30% PEG 300+ddH2O is a clear solution, and is for injection.

  • Question 3:

    How long can the chemical compound be stable in DMEM at 4 °C?

  • Answer:

    The compound is stable in DMEM at 4 degree for one week.

PARP Signaling Pathway Map

PARP Inhibitors with Unique Features

Related PARP Products5

Tags: buy Olaparib (AZD2281, Ku-0059436) | Olaparib (AZD2281, Ku-0059436) supplier | purchase Olaparib (AZD2281, Ku-0059436) | Olaparib (AZD2281, Ku-0059436) cost | Olaparib (AZD2281, Ku-0059436) manufacturer | order Olaparib (AZD2281, Ku-0059436) | Olaparib (AZD2281, Ku-0059436) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID